AFMAnalyze: Software Automation and Analysis of Atomic Force Microscopy (AFM) Data
Genetic Mutations Associated with Stuttering
Myosin-Based Protein-Protein Interaction Assay
TMC1, a Deafness-Related Gene
Phenylthiocarbamide (PTC) Taste Receptor
Haplotypes of Human Bitter Taste Receptor Genes
Functions and Targets of Therapeutic MicroRNAs to Treat and Diagnose Cancer
This technology includes a method to identify potentially therapeutic microRNAs in cancer, particularly squamous cell carcinoma of the head and neck (HNSCC). This approach first utilizes a large and publicly available expression dataset, which is then validated by a smaller independent dataset to determine deregulated microRNAs expression. These results are then intersected with in vitro functional anti-proliferative screening data to select for microRNAs that play a functional tumor suppressive role and likely serve as therapeutic targets.
Concurrent Use of Atorvastatin During Chemotherapy Reduces Cisplatin-induced Ototoxicity
This technology includes the use of atorvastatin, a medication to manage hypercholesterolemia, as a method to protect patients receiving cisplatin from hearing loss. Cisplatin chemotherapy is indicated in various cancer types in adults and children and is known to cause hearing loss. A patient on atorvastatin during chemotherapy is 46% less likely to acquire a significant cisplatin-induced hearing loss relative to a non-statin user. Atorvastatin is an FDA-approved medication routinely prescribed and well-tolerated clinically.
Stable Cell Line for Large Scale Production of Human Retinoschisin for Ocular Therapy
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a stable cell line for the production of human Retinoschisin (RS1) for therapeutic applications in ocular diseases.